Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction

References

• Pedersen F, Butrymovich V, Kelbæk H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. 2014;64(20):2101–2108. doi:10.1016/j.jacc.2014.08.037
   PubMed Web of Science ®Google Scholar
• Fokkema ML, James SK, Albertsson P, et al. Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish coronary angiography and angioplasty registry). J Am Coll Cardiol. 2013;61(12):1222–1230. doi:10.1016/j.jacc.2013.01.007
   PubMed Web of Science ®Google Scholar
• Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. 2014;35(29):1957–1970. doi:10.1093/eurheartj/eht529
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–233. doi:10.1016/S0140-6736(08)61076-4
   PubMed Web of Science ®Google Scholar
• Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation. 2005;112(23):3554–3561. doi:10.1161/CIRCULATIONAHA.105.563452
   PubMed Web of Science ®Google Scholar
• Langlois MR, Sniderman AD. Non-HDL cholesterol or apoB: which to Prefer As A Target For The Prevention Of Atherosclerotic Cardiovascular Disease? Curr Cardiol Rep. 2020;22(8):67. doi:10.1007/s11886-020-01323-z
   PubMed Web of Science ®Google Scholar
• de Nijs T, Sniderman A, de Graaf J. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management. Crit Rev Clin Lab Sci. 2013;50(6):163–171. doi:10.3109/10408363.2013.847897
   PubMed Web of Science ®Google Scholar
• Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148–154. doi:10.1016/j.pathol.2018.11.006
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35(5):779–792. doi:10.1016/S0022-2275(20)39173-2
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med. 2006;259(5):493–519. doi:10.1111/j.1365-2796.2006.01643.x
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026–2033. doi:10.1016/S0140-6736(01)07098-2
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255(2):188–205. doi:10.1046/j.1365-2796.2003.01276.x
   PubMed Web of Science ®Google Scholar
• Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med. 2006;259(5):437–446. doi:10.1111/j.1365-2796.2006.01648.x
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361(9359):777–780. doi:10.1016/S0140-6736(03)12663-3
   PubMed Web of Science ®Google Scholar
• Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259(3):247–258. doi:10.1111/j.1365-2796.2006.01616.x
   PubMed Web of Science ®Google Scholar
• Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease. J Am Coll Cardiol. 2020;75(17):2122–2135. doi:10.1016/j.jacc.2020.02.059
   PubMed Web of Science ®Google Scholar
• Li J, Wang W, Han L, et al. Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model. Acta Biochim Biophys Sin. 2017;49(2):149–158. doi:10.1093/abbs/gmw128
   Google Scholar
• Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest. 1988;82(3):803–807. doi:10.1172/JCI113682
   PubMed Web of Science ®Google Scholar
• Patel S, Di Bartolo BA, Nakhla S, et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis. 2010;212(2):392–397. doi:10.1016/j.atherosclerosis.2010.05.035
   PubMed Web of Science ®Google Scholar
• Walldius G, de Faire U, Alfredsson L, et al. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-experience from the Swedish AMORIS cohort: a cohort study. PLoS Med. 2021;18(12):e1003853. doi:10.1371/journal.pmed.1003853
   PubMed Web of Science ®Google Scholar
• Goswami B, Rajappa M, Mallika V, Kumar S, Shukla DK. Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. Acta Cardiol. 2008;63(6):749–755. doi:10.2143/AC.63.6.2033393
   PubMed Web of Science ®Google Scholar
• Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am Heart J. 2004;148(4):596–601. doi:10.1016/j.ahj.2004.03.021
   PubMed Web of Science ®Google Scholar
• van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. 2007;146(9):640–648. doi:10.7326/0003-4819-146-9-200705010-00007
   PubMed Web of Science ®Google Scholar
• Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26(3):271–278. doi:10.1093/eurheartj/ehi003
   PubMed Web of Science ®Google Scholar
• Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis. 1997;129(2):221–230. doi:10.1016/S0021-9150(96)06030-3
   PubMed Web of Science ®Google Scholar
• Li T, Yuan D, Wang P, et al. Associations of lipid measures with total occlusion in patients with established coronary artery disease: a cross-sectional study. Lipids Health Dis. 2022;21(1):118. doi:10.1186/s12944-022-01733-8
   PubMed Web of Science ®Google Scholar
• Song Y, Yang Y, Zhang J, et al. The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography. Lipids Health Dis. 2015;14(1):150. doi:10.1186/s12944-015-0155-6
   PubMedGoogle Scholar
• Yaseen RI, El-Leboudy MH, El-Deeb HM. The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome. Egypt Heart J. 2021;73(1):24. doi:10.1186/s43044-021-00150-z
   PubMedGoogle Scholar
• Zheng KH, Arsenault BJ, Kaiser Y, et al. apoB/apoA-I ratio and Lp(a) associations with aortic valve stenosis incidence: insights from the EPIC-Norfolk prospective population study. J Am Heart Assoc. 2019;8(16):e013020. doi:10.1161/JAHA.119.013020
   PubMed Web of Science ®Google Scholar
• Ivert T, Hammar N, Talbäck M, Malmström H, Leander K, Walldius G. Elevated Apolipoprotein B/A-1 ratio is associated with an increased risk of aortic stenosis: experience from the AMORIS cohort. Heart Lung Circ. 2021;30(7):1050–1057. doi:10.1016/j.hlc.2020.12.005
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang D, Song Z, et al. Elevated ApoB/ApoA-Ι ratio is associated with poor outcome in acute ischemic stroke. J Clin Neurosci. 2023;107:138–143. doi:10.1016/j.jocn.2022.11.007
   PubMed Web of Science ®Google Scholar
• Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J. 2009;30(17):2137–2146. doi:10.1093/eurheartj/ehp221
   PubMed Web of Science ®Google Scholar
• Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. BMJ. 1991;303(6794):89–92. doi:10.1136/bmj.303.6794.89
   PubMedGoogle Scholar
• Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke. 2004;35(10):2248–2252. doi:10.1161/01.STR.0000140629.65145.3c
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–4806. doi:10.1093/eurheartj/ehab551
   PubMed Web of Science ®Google Scholar
• Webb RJ, Mazidi M, Lip GYH, Kengne AP, Banach M, Davies IG. The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B. Nutr Metab Cardiovasc Dis. 2022;32(3):605–615. doi:10.1016/j.numecd.2021.12.004
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298–1309. doi:10.1161/CIRCULATIONAHA.113.003008
   PubMed Web of Science ®Google Scholar
• Li L, Ma Y, Geng XB, et al. Platelet-to-lymphocyte ratio relates to poor prognosis in elderly patients with acute myocardial infarction. Aging Clin Exp Res. 2021;33(3):619–624. doi:10.1007/s40520-020-01555-7
   PubMed Web of Science ®Google Scholar
• Ji Z, Liu G, Guo J, et al. The neutrophil-to-lymphocyte ratio is an important indicator predicting in-hospital death in AMI patients. Front Cardiovasc Med. 2021;8:706852. doi:10.3389/fcvm.2021.706852
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen S, Han Y, Xu Q, Zhao X. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are important indicators for predicting in-hospital death in elderly AMI patients. J Inflamm Res. 2023;16:2051–2061. doi:10.2147/JIR.S411086
   PubMed Web of Science ®Google Scholar
• Gheeraert PJ, De Buyzere ML, Taeymans YM, et al. Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic review and meta-analysis. Eur Heart J. 2006;27(21):2499–2510. doi:10.1093/eurheartj/ehl218
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61. doi:10.1016/j.atherosclerosis.2019.12.005
   PubMed Web of Science ®Google Scholar
• Rakowski T, Węgiel M, Siudak Z, et al. Prevalence and predictors of coronary artery perforation during percutaneous coronary interventions (from the ORPKI National Registry in Poland). Am J Cardiol. 2019;124(8):1186–1189. doi:10.1016/j.amjcard.2019.07.021
   PubMed Web of Science ®Google Scholar
• Zabojszcz M, Januszek R, Siudak Z, et al. Association between the mortality rate and operator volume in patients undergoing emergency or elective percutaneous coronary interventions. Kardiol Pol. 2020;78(2):138–146. doi:10.33963/KP.15123
   PubMed Web of Science ®Google Scholar
• Tokarek T, Dziewierz A, Plens K, et al. Percutaneous coronary intervention during on- and off-hours in patients with ST-segment elevation myocardial infarction. Hell J Cardiol. 2021;62(3):212–218. doi:10.1016/j.hjc.2021.01.011
   PubMed Web of Science ®Google Scholar